Australia's NeuroScientific Biopharmaceuticals rises on ethics approval for drug trial

Neuroscientific Biopharmaceuticals

07/06/2022 03:36

** Shares of NeuroScientific Biopharmaceuticals Ltd  NSB.AX 
rise nearly 11% to A$0.255, their highest since May 3
    ** Drugmaker for neuro-related conditions says it got
approval from Australia's Human Research Ethics Committee for
its first clinical trial of drug candidate EmtinB  urn:newsml:reuters.com:*:nASXc6QRF2
    ** EmtinB will be assessed for efficacy against
neurodegenerative conditions, like Alzheimer's disease and
multiple sclerosis
    ** Co says the early-phase clinical trial of EmtinB will be
undertaken by Western Australia-based clinical research partner
Linear Clinical Research
    ** Says clinical trial activities are expected to commence
immediately, including recruitment of subjects
    ** Stock posts its biggest intraday pct gain since May 30
    ** NSB had risen 31.3% this year, as of last close

 (Reporting by Savyata Mishra in Bengaluru)
 ((Savyata.mishra@thomsonreuters.com))